JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2003; 42:1348-1356, doi:10.1016/S0735-1097(03)01040-4
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, M.

CLINICAL RESEARCH: CLINICAL TRIAL

The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI)

A randomized trial

Marc Cohen, MD, FACC*,*, Gian Franco Gensini, MD{dagger}, Frans Maritz, MD{ddagger}, Enrique P. Gurfinkel, MD, PhD, FACC§, Kurt Huber, MD, FACC||, Ari Timerman, MD, PhD, Maria Krzeminska-Pakula, MD#, Nicolas Danchin, MD, FACC**, Harvey D. White, DSc{dagger}{dagger}, Jose Santopinto, MD, FACC{ddagger}{ddagger}, Frederique Bigonzi, MD§§, Carole Hecquet, MS§§, Luc Vittori, MS§§ TETAMI Investigators

* Newark Beth Israel Medical Center, Newark, New Jersey, USA
{dagger} University of Florence, Florence, Italy
{ddagger} Karl Bremer Hospital, Bellville, South Africa
§ Favaloro Foundation, Buenos Aires, Argentina
|| University Clinic for Internal Medicine, Vienna, Austria
Dante Pazzanese Institute of Cardiology, São Paulo, Brazil
# Medical University Lodz, Lodz, Poland
** Georges Pompidou Hospital, Paris, France
{dagger}{dagger} Green Lane Hospital, Auckland, New Zealand
{ddagger}{ddagger} Leonidas Lucero Municipal Hospital, Bahia Blanca, Argentina
§§ Aventis Pharmaceuticals, Paris, France

Manuscript received March 12, 2003; revised manuscript received April 28, 2003, accepted May 9, 2003.

* Reprint requests and correspondence: Dr. Marc Cohen, Cardiac Catheterization Laboratory, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA.
marcohen{at}sbhcs.com

OBJECTIVES: The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion.

BACKGROUND: An optimal treatment strategy has not been identified for the many STEMI patients ineligible for acute reperfusion.

METHODS: A total of 1,224 patients were enrolled in 91 centers in 14 countries between July 1999 and July 2002. Patients with STEMI ineligible for reperfusion were randomized to enoxaparin, enoxaparin plus tirofiban, UFH, or UFH plus tirofiban. All patients received oral aspirin. The primary efficacy end point was the 30-day combined incidence of death, reinfarction, or recurrent angina; the primary analysis was the comparison of the pooled enoxaparin and UFH groups.

RESULTS: The incidence of the primary efficacy end point was 15.7% enoxaparin versus 17.3% for UFH (odds ratio 0.89 [95% confidence interval {CI} = 0.66 to 1.21]) and 16.6% for tirofiban versus 16.4% for placebo (odds ratio 1.02 [95% CI 0.75 to 1.38]). The Thrombolysis In Myocardial Infarction (TIMI) major hemorrhage rate was 1.5% for enoxaparin versus 1.3% for UFH (odds ratio 1.16 [95% CI 0.44 to 3.02]) and 1.8% versus 1% for tirofiban versus placebo (odds ratio 1.82 [95% CI 0.67 to 4.95]).

CONCLUSIONS: This study did not show that enoxaparin significantly reduced the 30-day incidence of death, reinfarction, and recurrent angina compared with UFH in non-reperfused STEMI patients. However, enoxaparin appears to have a similar safety and efficacy profile to UFH and may be an alternative treatment. Additional therapy with tirofiban did not appear beneficial.

Abbreviations and Acronyms
  aPTT = activated partial thromboplastin time
  CABG = coronary artery bypass grafting
  CI = confidence interval
  LMWH = low-molecular-weight heparin
  MI = myocardial infarction
  PCI = percutaneous coronary interventions
  PTCA = percutaneous transluminal coronary angioplasty
  STEMI = ST-segment elevation myocardial infarction
  TETAMI = Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous UFH With and Without Tirofiban in the Treatment of Acute Myocardial Infarction in patients ineligible for reperfusion
  UFH = unfractionated heparin




This article has been cited by other articles:


Home page
ChestHome page
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 708S - 775S.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Oldgren, L. Wallentin, R. Afzal, J.-P. Bassand, A. Budaj, S. Chrolavicius, K. A.A. Fox, C. B. Granger, S. R. Mehta, P. Pais, et al.
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment
Eur. Heart J., February 1, 2008; 29(3): 315 - 323.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions
Circulation, December 19, 2006; 114(25): 2871 - 2891.
[Full Text] [PDF]


Home page
CirculationHome page
J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown, and S. Yusuf
Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials
Circulation, December 20, 2005; 112(25): 3855 - 3867.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Part 5: Acute Coronary Syndromes
Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72.
[Full Text] [PDF]


Home page
JAMAHome page
A. Schomig, G. Ndrepepa, and A. Kastrati
Mechanical Reperfusion More Than 12 Hours After Acute Myocardial Infarction--Reply
JAMA, October 26, 2005; 294(16): 2031 - 2032.
[Full Text] [PDF]


Home page
JAMAHome page
A. Schomig, J. Mehilli, D. Antoniucci, G. Ndrepepa, C. Markwardt, F. Di Pede, S. G. Nekolla, K. Schlotterbeck, H. Schuhlen, J. Pache, et al.
Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset: A Randomized Controlled Trial
JAMA, June 15, 2005; 293(23): 2865 - 2872.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J. S Kalus and L. R Moser
Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction
Ann. Pharmacother., March 1, 2005; 39(3): 481 - 491.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Kastrati, J. Mehilli, S. Nekolla, H. Bollwein, S. Martinoff, J. Pache, H. Schuhlen, M. Seyfarth, M. Gawaz, F.-J. Neumann, et al.
A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy
J. Am. Coll. Cardiol., March 3, 2004; 43(5): 734 - 741.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2003 by the American College of Cardiology Foundation.